Merck to acquire biopharmaceutical company Idenix for $3.85 billion
12:42 PM | June 9, 2014 | Natasha Alperowicz
Merck said today that it has entered into a definitive agreement to acquire of biopharmaceuticals company Idenix Pharmaceuticals (Cambridge, MA) for $24.50/share in cash. The boards of directors of...
This information is only available to subscribers.
chemweek.com is the one stop platform for chemical news, data and analysis across all industry sectors and geographies.